About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01154426

Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies

Study identifier: NCT01154426
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Solid tumor with progressive disease following therapy or for which acceptable standard treatment does not exist
  • No more than 2 prior chemotherapeutic regimens
  • Must have a known BRCA mutation or willingness to undergo BRCA mutation analysis
  • No prior PARP inhibitor treatment

Type of study:

Phase I study

Treatment:

21-day cycles where participants receive veliparib twice daily on days 1-14 and gemcitabine hydrochloride IV on days 1, 8, and 15

Study sites:

Pennsylvania
Hershey
Penn State Milton S Hershey Medical Center
Contact: Chandra P. Belani 717-531-1078 cbelani@psu.edu

Pittsburgh
University of Pittsburgh Cancer Institute
Contact: Edward Chu 412-623-5898 chue2@upmc.edu

Magee-Womens Hospital - University of Pittsburgh Medical Center
Contact: Robert P. Edwards redwards@mail.magee.edu

UPMC Hillman Cancer Center
Contact: Adam M. Brufsky brufskyam@upmc.edu

Page updated 06/13/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org